Yamasaki T et al. |
Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. |
|
Cell Transplant |
pmid:9710310
|
Krieger S |
Multiple sclerosis therapeutic pipeline: opportunities and challenges. |
|
Mt. Sinai J. Med. |
pmid:21425264
|
Derwenskus J |
Current disease-modifying treatment of multiple sclerosis. |
|
Mt. Sinai J. Med. |
pmid:21425262
|
Huizinga R and Voyer T |
New paradigms in immunosuppression. |
|
CANNT J |
pmid:14596200
|
Chun J and Hartung HP |
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. |
|
Clin Neuropharmacol |
pmid:20061941
|
Pin D et al. |
An emulsion restores the skin barrier by decreasing the skin pH and inflammation in a canine experimental model. |
|
J. Comp. Pathol. |
pmid:24975893
|
Duan RD |
Anticancer compounds and sphingolipid metabolism in the colon. |
|
In Vivo |
pmid:15796189
|
Yanagawa Y et al. |
FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. |
|
Transplant. Proc. |
pmid:10083548
|
Suzuki T et al. |
Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. |
|
Transplant. Proc. |
pmid:10083540
|
Kunikata S et al. |
Immunosuppressive action of FTY720 for renal allograft a rat model. |
|
Transplant. Proc. |
pmid:10083517
|